Søgaard Kirstine Kobberøe, Farkas Dóra Körmendiné, Ehrenstein Vera, Bhaskaran Krishnan, Bøtker Hans Erik, Sørensen Henrik Toft
From Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Denmark (K.K.S., D.K.F., V.E., H.T.S.); Non-Communicable Diseases Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom (K.B.) Department of Cardiology, Aarhus University Hospital, Skejby, Denmark (H.E.B.); and Department of Health Research and Policy (Epidemiology), Stanford University, CA (H.T.S.).
Circulation. 2017 Sep 12;136(11):996-1006. doi: 10.1161/CIRCULATIONAHA.116.024041. Epub 2017 Jun 29.
Pericarditis may be a serious complication of malignancy. Its significance as a first symptom of occult cancer and as a prognostic factor for cancer survival is unknown.
Using Danish medical databases, we conducted a nationwide cohort study of all patients with a first-time diagnosis of pericarditis during 1994 to 2013. We excluded patients with previous cancer and followed up the remaining patients for subsequent cancer diagnosis until November 30, 2013. We calculated risks and standardized incidence ratios of cancer for patients with pericarditis compared with the general population. We assessed whether pericarditis predicts cancer survival by the Kaplan-Meier method and Cox regression using a matched comparison cohort of cancer patients without pericarditis.
Among 13 759 patients with acute pericarditis, 1550 subsequently were diagnosed with cancer during follow-up. The overall cancer standardized incidence ratio was 1.5 (95% confidence interval [CI], 1.4-1.5), driven predominantly by increased rates of lung, kidney, and bladder cancer, lymphoma, leukemia, and unspecified metastatic cancer. The <3-month cancer risk among patients with pericarditis was 2.7%, and the standardized incidence ratio was 12.4 (95% CI, 11.2-13.7). The 3- to <12-month standardized incidence ratio of cancer was 1.5 (95% CI, 1.2-1.7), subsequently decreasing to 1.1 (95% CI, 1.0-1.2). Three-month survival after the cancer diagnosis was 80% and 86% among those with and without pericarditis, respectively, and the hazard ratio was 1.5 (95% CI, 1.3-1.8). One-year survival was 65% and 70%, respectively, corresponding to a 3- to <12-month hazard ratio of 1.3 (95% CI, 1.1-1.5).
Pericarditis may be a marker of occult cancer and augurs increased mortality after a cancer diagnosis.
心包炎可能是恶性肿瘤的严重并发症。其作为隐匿性癌症的首发症状以及癌症生存预后因素的意义尚不清楚。
利用丹麦医学数据库,我们对1994年至2013年期间首次诊断为心包炎的所有患者进行了一项全国性队列研究。我们排除了既往有癌症的患者,并对其余患者进行随访,直至2013年11月30日以诊断后续癌症。我们计算了心包炎患者与普通人群相比患癌的风险和标准化发病率。我们使用Kaplan-Meier方法和Cox回归,通过匹配无心包炎的癌症患者比较队列,评估心包炎是否可预测癌症生存情况。
在13759例急性心包炎患者中,1550例在随访期间随后被诊断患有癌症。总体癌症标准化发病率为1.5(95%置信区间[CI],1.4 - 1.5),主要由肺癌、肾癌、膀胱癌、淋巴瘤、白血病及未明确的转移性癌症发病率增加所致。心包炎患者中<3个月的患癌风险为2.7%,标准化发病率为12.4(95%CI,11.2 - 13.7)。3至<12个月的癌症标准化发病率为1.5(95%CI,1.2 - 1.7),随后降至1.1(95%CI,1.0 - 1.2)。癌症诊断后3个月的生存率在有心包炎和无心包炎患者中分别为80%和86%,风险比为1.5(95%CI,1.3 - 1.8)。1年生存率分别为65%和70%,对应3至<12个月的风险比为1.3(95%CI,1.1 - 1.5)。
心包炎可能是隐匿性癌症的一个标志,并预示癌症诊断后死亡率增加。